JB Chemicals Q4 Results FY26 PAT Rs 101 Crore Down 30 Percent Revenue Rs 904 Crore EBITDA 27 Percent
- May 12, 2026
- Posted by: Neeraj Pandey
- Category: News
JB Chemicals and Pharmaceuticals Q4 results for FY26 reported a net profit of Rs 101 crore for the quarter ended March 31, 2026, down 30% year on year, impacted by non-cash ESOP charges and other exceptional items. The JB Chemicals Q4 results were announced on May 11, 2026, with Q4 revenue at Rs 904 crore and EBITDA of Rs 241 crore at a margin of 27%.
The JB Chemicals Q4 FY26 adjusted net profit after tax, accounting for non-cash ESOP charges and exceptional items, was Rs 150 crore. Gross margins remained strong at 70%. The JB Chemicals Q4 India business showed modest 2% YoY growth to Rs 526 crore for the quarter but 9% growth for the full fiscal year to Rs 2,461 crore. The companys chronic portfolio outperformed with 19% growth against industry’s 14%.
Get Free Stock Recommendations on Univest
JB Chemicals and Pharmaceuticals Q4 FY26 Results at a Glance
| Metric | Q4 FY26 | Change / Context |
|---|---|---|
| Q4 Net Profit PAT | Rs 101 crore | -30% YoY |
| Q4 Adjusted PAT | Rs 150 crore | Excl. ESOP & exceptional |
| Q4 Revenue | Rs 904 crore | Stable |
| Q4 EBITDA | Rs 241 crore | 27% margin |
| Q4 Gross Margin | 70% | Strong |
| India FY26 Revenue | Rs 2,461 crore | +9% YoY |
Track live JB Chemicals financials, analyst ratings and peer comparisons on the Univest Screener.
Key Highlights from JB Chemicals and Pharmaceuticals Q4 FY26 Results
Chronic Portfolio Outperforms Industry
The JB Chemicals Q4 results FY26 India business chronic portfolio grew 19% versus the industry’s 14% as per IQVIA MAT March 2026. The JB Chemicals Q4 results highlight the strength of established brands in cardiovascular, antifungal, and other therapeutic segments. India business Q4 contribution of Rs 526 crore remains the largest segment at 58% of total revenue. Domestic growth acceleration in FY26 at 9% reflects improved field force productivity and chronic brand investments.
International Formulations Face Headwinds
JB Chemicals Q4 results FY26 international formulations revenue declined 9% for the quarter to Rs 259 crore, though the full year saw 2% growth to Rs 1,154 crore. The JB Chemicals Q4 results reflect integration challenges and competitive dynamics in export markets including the US, Russia, and Africa. The company is undergoing integration with its parent following the KKR acquisition, which impacts quarterly financials through ESOP and restructuring charges.
What Drove JB Chemicals and Pharmaceuticals Q4 FY26 Performance
The JB Chemicals Q4 results were driven by steady India chronic business growth and maintained EBITDA margins despite one-off charges. The JB Chemicals Q4 reported PAT decline of 30% is largely attributable to non-cash ESOP charges, making adjusted PAT of Rs 150 crore more representative of underlying performance. Gross margin at 70% demonstrates strong product mix and formulation premium.
Outlook for FY27 After JB Chemicals and Pharmaceuticals Q4 Results
Following the JB Chemicals Q4 results FY26, FY27 outlook depends on India chronic portfolio growth, international recovery, and integration benefits from parent company synergies. The JB Chemicals Q4 results FY27 trajectory benefits from rising healthcare consumption in India, therapeutic expansion, and product launches in key chronic segments. ESOP amortization impact will gradually reduce in FY27.
Conclusion
JB Chemicals Q4 results FY26 delivered Q4 adjusted PAT of Rs 150 crore with revenue Rs 904 crore and EBITDA margin 27%. The JB Chemicals Q4 results India FY26 growth of 9% and chronic portfolio +19% confirm brand strength. Investors tracking JB Chemicals Q4 results should watch adjusted PAT, India chronic growth, and international formulations recovery.
Download the Univest iOS App or Univest Android App for live Q4 results tracking and expert research.
Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. Univest analysts are SEBI-registered research analysts (SEBI RA: INH000012449). Verify all numbers before investing. Consult a SEBI-registered financial advisor before making any investment decisions.
Frequently Asked Questions
What was JB Chemicals Q4 FY26 PAT?
JB Chemicals Q4 results FY26 reported Q4 net profit of Rs 101 crore (-30% YoY) impacted by non-cash ESOP charges. Adjusted PAT excluding ESOP and exceptional items was Rs 150 crore, with EBITDA of Rs 241 crore at 27% margin.
Why did JB Chemicals Q4 PAT decline?
JB Chemicals Q4 results FY26 PAT declined 30% due to non-cash ESOP charges and other exceptional items related to company integration. Adjusted PAT at Rs 150 crore better reflects underlying business performance.
What is JB Chemicals India business performance?
India business in the JB Chemicals Q4 results FY26 contributed Rs 526 crore in Q4 (+2% YoY) and Rs 2,461 crore for FY26 (+9%), with chronic portfolio growing 19% versus industry 14% per IQVIA MAT March 2026.
What is JB Chemicals gross margin?
Gross margin in the JB Chemicals Q4 results FY26 stood at 70%, reflecting strong formulation product mix and pricing power in the pharmaceutical segment.
What does JB Chemicals do?
JB Chemicals and Pharmaceuticals manufactures branded pharmaceutical formulations in India and exports to international markets. As reflected in the JB Chemicals Q4 results FY26, key segments include India branded formulations, contract manufacturing, and international formulations.
Recent Article
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026
Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026
